Precision Health Research, Singapore (PRECISE) formalized a precompetitive partnership with Alnylam, Bayer, Boehringer Ingelheim and Novo Nordisk to analyze data from PRECISE‑SG100K, a population project of 100,000 Singapore residents. The collaboration will use whole‑genome sequences and SomaScan proteomics to study Asian genetic diversity, biomarkers and disease risk—data intended to support diagnostics and therapeutic development tailored to Asian populations. PRECISE said partners will fund research activities, provide analytical support and help build local scientific capacity, addressing diversity gaps in global genomic datasets.